Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 14, 2026

SocGen flags rare market extremes as tech volatility reaches multi-year highs

View original at seekingalpha.com
SocGen flags rare market extremes as tech volatility reaches multi-year highs [Digital Intelligence - AI Icon Illuminated Against Financial Data and Binary Streams] J Studios Investors are piling into semiconductor and technology-related options at a pace that is pushing several market indicators to extremes not seen s…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Average single-stock volatility within the S&P 500 in early June sat in the 95th percentile of historical observations, with much of the increase driven by technology companies

    60% confidence
  • Technology sector earnings growth has climbed to its highest level in roughly 30 years, creating larger gaps between winners and losers and increasing uncertainty around future expectations

    60% confidence
  • Rising volatility, extreme options activity and historically low correlations suggest markets may be more vulnerable to sharp rotations if expectations change

    60% confidence
  • The unusual combination of low correlation and elevated volatility suggests investors are making increasingly aggressive bets on individual sectors and stocks rather than the broader market

    60% confidence
  • Enthusiasm has reached levels where positive news itself may be contributing to heightened volatility rather than dampening it

    60% confidence
  • Nasdaq 100 single-stock volatility has reached its highest level since 2011

    60% confidence
  • The correlation between global cyclical and defensive stocks has fallen toward zero, a level even lower than that seen in the aftermath of the technology bubble burst more than two decades ago

    60% confidence
  • The average one-year implied volatility for Russell 2000 companies has climbed above 100, the highest level in data going back to 2014

    60% confidence
  • Investors are piling into semiconductor and technology-related options at a pace that is pushing several market indicators to extremes not seen since the dot-com era

    60% confidence
  • The cost of obtaining leverage through derivatives markets on the Nasdaq 100 is at its highest level for this point in the year since 2011

    60% confidence
  • The notional value of options trading on the ETFs has increased roughly fourfold, while option premium turnover has surged about eightfold

    60% confidence
  • Investors are increasingly treating technology and AI-related assets less like traditional equity holdings and more like vehicles for tactical trading

    60% confidence
  • The two largest U.S. semiconductor ETFs (SMH and SOXX) have doubled in size this year, while options trading activity tied to those funds has exploded

    60% confidence
  • Investors have spent more than $500 million on options linked to the two funds on each of the past three trading days

    60% confidence
  • Implied correlation within the S&P 500 has climbed above levels recorded during the dot-com bubble

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com